Latest News and Press Releases

TORONTO, Jan. 09, 2024 (GLOBE NEWSWIRE) -- via IBN --  Nextech3D.AI (OTCQX: NEXCF) (CSE: NTAR) (FSE: 1SS), an AI-3D model supplier for major e-commerce retailers announces an uptick in sales with a...

Spaceback, the leading creative automation platform announced its new offering: Social CTV. CB2 pilots the new offering to bring social media posts to CTV.

Phase 3 study of lenabasum in dermatomyositis on schedule for topline data in Q2 2021 Company focused on advancing cannabinoid programs in metabolic diseases and cancer into the clinic in 2022Corbus...

 ●Phase 3 study of lenabasum in dermatomyositis on schedule for topline data in Q2 2021  ●Company focused on advancing in-house programs in metabolic diseases, fibrotic disorders, and cancer with...

•   Company to host conference call and webcast on Monday, March 15, 2021 at 8:30 a.m. ET Norwood, MA, March 08, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP)...

Phase 2 systemic sclerosis (SSc) analyses show ACR CRISS score correlates with improvements from baseline in how patients feel and function through two years in the lenabasum Phase 2 open-label...

Phase 2b study of lenabasum for treatment of cystic fibrosis enriched for patients at high risk of pulmonary exacerbationsStudy on target for data readout in late summer 2020 Norwood, MA, June ...

Norwood, MA, May 15, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...

- Management to host conference call and webcast on Monday, May 11 at 8:30 a.m. ET- NORWOOD, MA, May 04, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or...

Norwood, MA, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...